163 related articles for article (PubMed ID: 37688927)
1. Serum neurofilament and glial fibrillary acidic protein in idiopathic and seropositive transverse myelitis.
Lee HL; Seok JM; Chung YH; Min JH; Baek SH; Kim SM; Sohn E; Kim J; Kang SY; Hong YH; Shin HY; Cho JY; Oh J; Lee SS; Kim S; Kim SH; Kim HJ; Kim BJ; Kim BJ
Mult Scler Relat Disord; 2023 Nov; 79():104957. PubMed ID: 37688927
[TBL] [Abstract][Full Text] [Related]
2. Serum biomarkers in myelin oligodendrocyte glycoprotein antibody-associated disease.
Kim H; Lee EJ; Kim S; Choi LK; Kim K; Kim HW; Kim KK; Lim YM
Neurol Neuroimmunol Neuroinflamm; 2020 May; 7(3):. PubMed ID: 32184342
[TBL] [Abstract][Full Text] [Related]
3. Plasma glial fibrillary acidic protein and neurofilament light chain in relation to disability worsening in multiple sclerosis.
Pauwels A; Van Schependom J; Devolder L; Van Remoortel A; Nagels G; Bjerke M; D'hooghe MB
Mult Scler; 2022 Oct; 28(11):1685-1696. PubMed ID: 36059263
[TBL] [Abstract][Full Text] [Related]
4. Clinical implication of serum biomarkers and patient age in inflammatory demyelinating diseases.
Lee EJ; Lim YM; Kim S; Choi L; Kim H; Kim K; Kim HW; Lee JS; Kim KK
Ann Clin Transl Neurol; 2020 Jun; 7(6):992-1001. PubMed ID: 32495489
[TBL] [Abstract][Full Text] [Related]
5. Serum Neurofilament Light and GFAP Are Associated With Disease Severity in Inflammatory Disorders With Aquaporin-4 or Myelin Oligodendrocyte Glycoprotein Antibodies.
Chang X; Huang W; Wang L; ZhangBao J; Zhou L; Lu C; Wang M; Yu J; Li H; Li Y; Zhao C; Lu J; Quan C
Front Immunol; 2021; 12():647618. PubMed ID: 33796113
[No Abstract] [Full Text] [Related]
6. Neurofilament light chain as a biomarker in neuromyelitis optica spectrum disorder: a comprehensive review and integrated analysis with glial fibrillary acidic protein.
Kim S; Lee JJ; Park JS; Kang M; Seok HY
Neurol Sci; 2024 Mar; 45(3):1255-1261. PubMed ID: 38141119
[TBL] [Abstract][Full Text] [Related]
7. Serum Biomarker Profiles Discriminate AQP4 Seropositive and Double Seronegative Neuromyelitis Optica Spectrum Disorder.
Carta S; Dinoto A; Capobianco M; Valentino P; Montarolo F; Sala A; Reindl M; Lo Re M; Chiodega V; Branger P; Audoin B; Aboab J; Papeix C; Collongues N; Kerschen P; Zephir H; Créange A; Bourre B; Schanda K; Flanagan EP; Redenbaugh V; Villacieros-Álvarez J; Arrambide G; Cobo-Calvo A; Ferrari S; Marignier R; Mariotto S
Neurol Neuroimmunol Neuroinflamm; 2024 Jan; 11(1):e200188. PubMed ID: 38134369
[TBL] [Abstract][Full Text] [Related]
8. Serum GFAP and NfL as disease severity and prognostic biomarkers in patients with aquaporin-4 antibody-positive neuromyelitis optica spectrum disorder.
Schindler P; Grittner U; Oechtering J; Leppert D; Siebert N; Duchow AS; Oertel FC; Asseyer S; Kuchling J; Zimmermann HG; Brandt AU; Benkert P; Reindl M; Jarius S; Paul F; Bellmann-Strobl J; Kuhle J; Ruprecht K
J Neuroinflammation; 2021 May; 18(1):105. PubMed ID: 33933106
[TBL] [Abstract][Full Text] [Related]
9. Association of serum neurofilament light chain and glial fibrillary acidic protein levels with cognitive decline in Parkinson's disease.
Mao S; Teng X; Li Z; Zu J; Zhang T; Xu C; Cui G
Brain Res; 2023 Apr; 1805():148271. PubMed ID: 36754139
[TBL] [Abstract][Full Text] [Related]
10. Serum neurofilament-light and glial fibrillary acidic protein levels in hydroxychloroquine-treated primary progressive multiple sclerosis.
Camara-Lemarroy C; Silva C; Gohill J; Yong VW; Koch M
Eur J Neurol; 2023 Jan; 30(1):187-194. PubMed ID: 36214614
[TBL] [Abstract][Full Text] [Related]
11. Serum glial fibrillary acidic protein and neurofilament light chain in treatment-naïve patients with unipolar depression.
Hviid CVB; Benros ME; Krogh J; Nordentoft M; Christensen SH
J Affect Disord; 2023 Oct; 338():341-348. PubMed ID: 37336248
[TBL] [Abstract][Full Text] [Related]
12. Longitudinal follow-up of serum biomarkers in patients with neuromyelitis optica spectrum disorder.
Kim H; Lee EJ; Kim S; Choi LK; Kim HJ; Kim HW; Chung K; Seo D; Moon S; Kim KK; Lim YM
Mult Scler; 2022 Apr; 28(4):512-521. PubMed ID: 34212756
[TBL] [Abstract][Full Text] [Related]
13. Serum glial fibrillary acidic protein correlates with multiple sclerosis disease severity.
Högel H; Rissanen E; Barro C; Matilainen M; Nylund M; Kuhle J; Airas L
Mult Scler; 2020 Feb; 26(2):210-219. PubMed ID: 30570436
[TBL] [Abstract][Full Text] [Related]
14. The relationship between serum neurofilament light chain and glial fibrillary acidic protein with the REM sleep behavior disorder subtype of Parkinson's disease.
Teng X; Mao S; Wu H; Shao Q; Zu J; Zhang W; Zhou S; Zhang T; Zhu J; Cui G; Xu C
J Neurochem; 2023 Apr; 165(2):268-276. PubMed ID: 36776136
[TBL] [Abstract][Full Text] [Related]
15. Relationship between increased serum neurofilament light chain and glial fibrillary acidic protein levels with non-motor symptoms in patients with Parkinson's disease.
Yin P; Niu X; Guan C; Zhang Z; Liu Y; Li J; Cui G; Zan K; Xu C
Psychogeriatrics; 2024 Mar; 24(2):415-425. PubMed ID: 38339819
[TBL] [Abstract][Full Text] [Related]
16. Serum neurofilament light chain and glial fibrillary acidic protein in AQP4-IgG-seropositive neuromyelitis optica spectrum disorders and multiple sclerosis: A cohort study.
Liu C; Lu Y; Wang J; Chang Y; Wang Y; Chen C; Liu Z; Kermode AG; Zhang Y; Qiu W
J Neurochem; 2021 Dec; 159(5):913-922. PubMed ID: 34278578
[TBL] [Abstract][Full Text] [Related]
17. Serum and cerebrospinal fluid neurofilament light chain and glial fibrillary acid protein levels in early and advanced stages of cerebral amyloid Angiopathy.
Rasing I; Voigt S; Koemans EA; de Kort AM; van Harten TW; van Etten ES; van Zwet EW; Stoops E; Francois C; Kuiperij BH; Klijn CJM; Schreuder FHBM; van der Weerd L; van Osch MJP; van Walderveen MAA; Verbeek MM; Terwindt GM; Wermer MJH
Alzheimers Res Ther; 2024 Apr; 16(1):86. PubMed ID: 38654326
[TBL] [Abstract][Full Text] [Related]
18. The effect of aerobic exercise on Neurofilament light chain and glial Fibrillary acidic protein level in patients with relapsing remitting type multiple sclerosis.
Ercan Z; Bilek F; Demir CF
Mult Scler Relat Disord; 2021 Oct; 55():103219. PubMed ID: 34433118
[TBL] [Abstract][Full Text] [Related]
19. NfL and GFAP in serum are associated with microstructural brain damage in progressive multiple sclerosis.
Ammitzbøll C; Dyrby TB; Börnsen L; Schreiber K; Ratzer R; Romme Christensen J; Iversen P; Magyari M; Lundell H; Jensen PEH; Sørensen PS; Siebner HR; Sellebjerg F
Mult Scler Relat Disord; 2023 Sep; 77():104854. PubMed ID: 37418931
[TBL] [Abstract][Full Text] [Related]
20. Glial fibrillary acidic protein: a potential biomarker for progression in multiple sclerosis.
Axelsson M; Malmeström C; Nilsson S; Haghighi S; Rosengren L; Lycke J
J Neurol; 2011 May; 258(5):882-8. PubMed ID: 21197541
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
